Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLR-108 PET Imaging in Metastatic Solid Tumors
NCT07728942Phase 1Recruiting
- Sponsor
- Solve Therapeutics
- Start
- Aug 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of SLR-108 in metastatic solid tumor (5 arms), sponsored by Solve Therapeutics. Primary endpoints: Optimal antibody protein dose at Day 14, Optimal administered activity at Day 14 and 1 more. Started Aug 2026; status: recruiting.
02
Drugs
SLR-108
03
Conditions
metastatic solid tumor
Beyond the preview
Go deeper on NCT07728942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07728942.